Cyclopharm (ASX:CYC) Institutional Ownership: 0.11% (As of Jul. 11, 2026)


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.53
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Institutional Ownership?

Cyclopharm ASX:CYC +2.94% 45 Institutional Ownership is 0.11% as of Jul. 11, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclopharm's institutional ownership is 0.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclopharm's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclopharm's Float Percentage Of Total Shares Outstanding is 0.00%.

Cyclopharm Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cyclopharm's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm Institutional Ownership Chart

Cyclopharm Historical Data

The historical data trend for Cyclopharm can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.13 0.13 0.13 0.13 0.13 0.12 0.13 0.11 0.11 0.11
ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.11% mean?
Cyclopharm (ASX:CYC) has a Institutional Ownership of 0.11% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cyclopharm and its competitors.
Is Cyclopharm's Institutional Ownership too high?
Cyclopharm's current Institutional Ownership is 0.11%. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Institutional Ownership compare to MCK and CAH?
Cyclopharm's Institutional Ownership of 0.11% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Distribution company?
A good Institutional Ownership depends on the Medical Distribution industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cyclopharm and its competitors. Cyclopharm's current Institutional Ownership is 0.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.53 — trading 36.7% below its estimated fair value. The current Institutional Ownership is 0.11%. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Institutional Ownership is 0.11% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.53 is trading 36.7% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Institutional Ownership: 0.11%
  • GF Value™: A$0.83 vs. price of A$0.53 (36.7% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.53
Price
A$0.83
GF Value